MacroGenics gets $50 million NIH contract

MacroGenics (Rockville, Md.) said it received a five-year $50 million contract from NIH's National Institute for Allergy and Infectious Diseases (NIAID) to develop the company's MGAWN1 to treat West Nile virus (WNV). The WNV contract will support manufacturing and development through Phase II testing. MGAWN1 is a humanized MAb that is expected to enter Phase I trials in the first half of 2007. MacroGenics also develops its MGVWN1 vaccine, which is in Phase I testing to prevent WNV infection. ...